NCT03706027 Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer
| NCT ID | NCT03706027 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2018-12-15 |
| Primary Completion | 2033-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2018-12-15 with a primary completion date of 2033-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be randomly assigned to either the 3 Fraction or 5 Fraction schedule of radiation. After patients complete radiation treatment, they will follow up with their radiation oncologist.
Eligibility Criteria
Inclusion Criteria: * Histological confirmation of non-small cell cancer will not be required as primary goal of this phase II trial is to look at toxicity. However, all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified. * Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC stage I or II based on only one of the following combinations of TNM staging: * T1, N0, M0 * T2 (≤ 5 cm), N0, M0 * Patients with hilar or mediastinal lymph nodes ≤ 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with \> 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. All patients with suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy and (if amenable) bronchoscopic biopsy (preferably navigational biopsy and/or endobronchial US guided biopsy). * Zubrod performance status 0-2 within 4 weeks of study entry. * Women of childbearing potential and male participants must use an effective contraceptive method. * Evaluations required at time of study entry: * History \& Physical by a radiation oncologist within 4 weeks of study entry; * Vitals within 4 weeks of study entry; * Evaluation by a thoracic surgeon (either via clinical examination and/or input at multidisciplinary tumor board) prior to study entry; * PFTs: Routine spirometry, lung volumes, diffusion capacity, and arterial blood gases within 8 weeks prior to study entry; * CT Chest within 6 weeks of study entry (preferably with intravenous contrast, unless medically contraindicated) - to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on this CT; * Whole body positron emission tomography (PET) scan using FDG with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions within 6 weeks prior to study entry. * Informed consent signed by the subject and a member of the study team. Exclusion Criteria: * Patients with central tumors. Specifically; central location implies a tumor inside the zone of the proximal bronchial tree defined as a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi * Evidence of regional or distant metastases after appropriate staging studies. * Synchronous primary NSCLC. * Those with prior malignancy in the past 2 years other than non-melanomatous skin cancer or in situ cancer or thyroid cancer. * Previous lung or mediastinal radiotherapy. * Plans for the patient to receive concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol. * Patients with active systemic, pulmonary or pericardial infection. * Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03706027 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03706027 currently recruiting?
Yes, NCT03706027 is actively recruiting participants. Contact the research team at deepinder_singh@urmc.rochester.edu for enrollment information.
Where is the NCT03706027 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT03706027 clinical trial?
NCT03706027 is sponsored by University of Rochester. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.